OBJECTIVE: The purpose of this study was to evaluate the long-term expression of a transgene and subsequent immune response after the injection of lentiviral vectors in a fetal rats. STUDY DESIGN: Fetal rats were injected in the liver, peritoneal cavity, or lung at E19 (term, E21) with a lentiviral vector expressing enhanced green fluorescent protein and luciferase. Controls received saline solution. After birth, full body bioluminescence was done at weeks 1, 4, 10, and 30 of life; seroconversion for the transgene was assessed. RESULTS: All surviving fetuses that had been injected in the liver (8/9 fetuses), peritoneum (3/3 fetuses), or lung (9/10 fetuses) showed a signal on bioluminescence imaging scan up to 30 weeks. None of the survivors displayed seroconversion against the transgene. CONCLUSION: In the rat model, the administration of lentiviral vectors into the fetal lung and liver resulted in long-term transgene expression without detectable humoral immune response.
OBJECTIVE: The purpose of this study was to evaluate the long-term expression of a transgene and subsequent immune response after the injection of lentiviral vectors in a fetal rats. STUDY DESIGN: Fetal rats were injected in the liver, peritoneal cavity, or lung at E19 (term, E21) with a lentiviral vector expressing enhanced green fluorescent protein and luciferase. Controls received saline solution. After birth, full body bioluminescence was done at weeks 1, 4, 10, and 30 of life; seroconversion for the transgene was assessed. RESULTS: All surviving fetuses that had been injected in the liver (8/9 fetuses), peritoneum (3/3 fetuses), or lung (9/10 fetuses) showed a signal on bioluminescence imaging scan up to 30 weeks. None of the survivors displayed seroconversion against the transgene. CONCLUSION: In the rat model, the administration of lentiviral vectors into the fetal lung and liver resulted in long-term transgene expression without detectable humoral immune response.
Authors: Marianne S Carlon; Jaan Toelen; Marina Mori da Cunha; Dragana Vidović; Anke Van der Perren; Steffi Mayer; Lourenço Sbragia; Johan Nuyts; Uwe Himmelreich; Zeger Debyser; Jan Deprest Journal: J Vis Exp Date: 2012-10-31 Impact factor: 1.355
Authors: Marianne Carlon; Jaan Toelen; Anke Van der Perren; Luk H Vandenberghe; Veerle Reumers; Lourenço Sbragia; Rik Gijsbers; Veerle Baekelandt; Uwe Himmelreich; James M Wilson; Jan Deprest; Zeger Debyser Journal: Mol Ther Date: 2010-07-27 Impact factor: 11.454
Authors: Luc Joyeux; Enrico Danzer; Maria P Limberis; Philip W Zoltick; Antoneta Radu; Alan W Flake; Marcus G Davey Journal: Hum Gene Ther Methods Date: 2014-04-21 Impact factor: 2.396
Authors: Alessandro Ruggiero; Daniel L J Thorek; Jamal Guenoun; Gabriel P Krestin; Monique R Bernsen Journal: Eur Radiol Date: 2011-07-07 Impact factor: 5.315
Authors: J Toelen; M Carlon; F Claus; R Gijsbers; I Sandaite; K Dierickx; R Devlieger; K Devriendt; A Debeer; M Proesmans; Z Debyser; A J Deprest Journal: Facts Views Vis Obgyn Date: 2011